RT Journal Article
T1 Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era
A1 Miguel, Sara de
A1 González-Camacho, Fernando
A1 Domenech Lucas, Miriam
A1 Sempere, Julio
A1 Vicioso, Dolores
A1 Sanz, Juan Carlos
A1 García Comas, Luis
A1 Ardanuy, Carmen
A1 Fenoll, Asunción
A1 Yuste, José
AB Background: Introduction of pneumococcal conjugate vaccines (PCVs) has reduced the disease caused by vaccine serotypesin children, providing herd protection to adults. However, the emergence of nonvaccine serotypes is of great concern worldwide.Methods: This study includes national laboratory data from invasive pneumococcal disease (IPD) cases that affected pediatricand adult populations during 2009–2019. The impact of implementing different vaccine strategies for immunocompetent adults bycomparing Spanish regions that used the 13-valent PCV (PCV13) vs regions that used the 23-valent pneumococcal polysaccharidevaccine (PPV23) was also analyzed for 2017−2019.Results: The overall reductions in IPD cases by PCV13 serotypes in children and adults were 88% and 59%, respectively, during2009–2019, with a constant increase in serotype 8 in adults since 2015. IPD cases by additional serotypes covered by PPV23 increased from 20% in 2009 to 52% in 2019. In children, serotype 24F was the most frequent in 2019, whereas serotypes 3 and 8 accounted for 36% of IPD cases in adults. Introduction of PCV13 or PPV23 in the adult calendar of certain Spanish regions reducedthe IPD cases by PCV13 serotypes by up to 25% and 11%, respectively, showing a decrease of serotype 3 when PCV13 was used.Conclusions: Use of PCV13 in children has affected the epidemiology, reducing the burden of IPD in children but also in adultsby herd protection; however, the increase in serotype 8 in adults is worrisome. Vaccination with PCV13 in adults seems to controlIPD cases by PCV13 serotypes including serotype 3.
PB Oxford University Press
SN 1058-4838
YR 2020
FD 2020-09-29
LK https://hdl.handle.net/20.500.14352/99070
UL https://hdl.handle.net/20.500.14352/99070
LA eng
NO Ministerio de Economía, Industria y Competitividad
NO Instituto de Salud Carlos III
DS Docta Complutense
RD 22 jul 2024